ClinicalTrials.gg
RecruitingNCT07301255Updated Sep 24, 2026

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

A Phase 2 interventional study of ENV-294 and Placebo in Asthma, sponsored by Enveda Therapeutics. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Enveda Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
857th of 1,353
50 · median 100
Started
2026
with 53 others
Phase 2
292 of 1,695
22 open now
Primary completion
2026-12
later than 42 of 183 live
Registered
1,650th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 857th largest by planned enrollment of the 1,353 interventional ones that give a count, is one of 54 that started in 2026, is one of 292 in phase 2, reaches primary completion later than 42 of the 183 other live ones, and was the 1,650th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).

Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma in Adults
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to read, understand, and sign an form before any study procedures
  • Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
  • Receiving stable treatment with an inhaled (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
  • Pre-bronchodilator between 50% and 80% of predicted normal at screening and baseline
  • Demonstrated bronchodilator reversibility
  • ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
  • History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care

Exclusion criteria

Exclusion Criteria:

  • Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
  • History of life-threatening asthma
  • Other significant pulmonary disease
  • Recent bronchial thermoplasty (within 2 years)
  • Uncontrolled current or recurrent concomitant illness
  • Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
  • Require medications or frequent systemic
  • Current smokers or former smokers with significant smoking history
  • Uncontrolled hypertension
  • Significant hepatic impairment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ENV-294 Treatment Arm

    ENV-294 will be administered to those participants randomized to the treatment arm.

    Drug: ENV-294

  • Placebo comparator
    Placebo Arm

    A placebo will be administered to those participants randomized to the placebo arm.

    Drug: Placebo

Interventions

  • ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

  • DrugPlacebo

    Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events

    Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug.

    Time frame: From first dose through approximately 16 weeks

Secondary outcomes

  1. Loss of Asthma Control Events

    Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria

    Time frame: Baseline to Week 12

  2. Time to Loss of Asthma Control

    Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol.

    Time frame: Baseline to Week 12

  3. To assess the efficacy of ENV-294 in participants with asthma

    Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry.

    Time frame: Baseline to Week 12

  4. To assess the efficacy of ENV-294 in participants with asthma

    Change from Baseline in the Asthma Control Questionnaire (ACQ-5)

    Time frame: Baseline to Week 12

  5. To assess the efficacy of ENV-294 in participants with asthma

    Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ)

    Time frame: Baseline to Week 12

  6. Plasma concentration of ENV-294

    Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug.

    Time frame: Baseline to Week 12

07

Study locations

20 of 20 sites recruiting
  • Enveda Investigative Site
    Birmingham, Alabama 35209, United States
    Recruiting
  • Enveda Investigative Site
    Los Angeles, California 90025, United States
    Recruiting
  • Enveda Investigative Site
    San Jose, California 95117, United States
    Recruiting
  • Enveda Investigative Site
    West Hills, California 91307, United States
    Recruiting
  • Enveda Investigative Site
    Colorado Springs, Colorado 80907, United States
    Recruiting
  • Enveda Investigative Site
    Hialeah, Florida 33012, United States
    Recruiting
  • Enveda Investigative Site
    Miami, Florida 33135, United States
    Recruiting
  • Enveda Investigative Site
    Albany, Georgia 31707, United States
    Recruiting
  • Enveda Investigative Site
    Maryville, Illinois 62062, United States
    Recruiting
  • Enveda Investigative Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Enveda Investigative Site
    Owensboro, Kentucky 42301, United States
    Recruiting
  • Enveda Investigative Site
    Boston, Massachusetts 02115, United States
    Recruiting
  • Enveda Investigative Site
    Southfield, Michigan 48075, United States
    Recruiting
  • Enveda Investigative Site
    St Louis, Missouri 63141, United States
    Recruiting
  • Enveda Investigative Site
    The Bronx, New York 10455, United States
    Recruiting
  • Enveda Investigative Site
    Clackamas, Oregon 97015, United States
    Recruiting
  • Enveda Investigative Site
    Medford, Oregon 97504, United States
    Recruiting
  • Enveda Investigative Site
    North Charleston, South Carolina 29406, United States
    Recruiting
  • Enveda Investigative Site
    McKinney, Texas 75069, United States
    Recruiting
  • Enveda Investigative Site
    Madison, Wisconsin 53792, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 11 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 24, 2025
StartActual
Jan 9, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301255
Lead sponsor
Enveda Therapeutics
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jan 9, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Clinical Operations
Contact
env-294.clinicaltrials@enveda.com
Gurpreet Ahluwalia, PhD
study director · Enveda Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENV-294

Start the discussion